甲酰胺,N-溴-N-(苯基甲基)- | 140669-91-6

• 中文名称: 甲酰胺,N-溴-N-(苯基甲基)-
• 英文名称: N-benzyl-N-bromoformamide
• CAS: 140669-91-6
• 化学式: C₈H₈BrNO
• 分子量: 214.062
• InChiKey: YCWGGGCNFCWKHX-UHFFFAOYSA-N

物化性质

• 沸点：
  277.6±33.0 °C(Predicted)
• 密度：
  1.528±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  甲酰胺,N-溴-N-(苯基甲基)- 、 环己烯 在 chromium dichloride 作用下， 生成 N-benzyl-N-(2-bromocyclohexyl)formamide
  参考文献：
  名称：

  Photolytic and chromium(II)-promoted addition reactions of N-halogenoformamides with alkenes

  摘要：

  Formamidyl radicals (HCONR) do not intramolecularly abstract hydrogen or cyclise onto aromatic rings, but do add intermolecularly to alkenes. The photolytic addition of N-halogenoformamides to alkenes is inhibited by N-alkylation. However, N-alkyl-N-halogenoformamides add to alkenes in the presence of chromium(II) species. The addition of N-halogenoformamides to alkenes occurs regiospecifically with formamidyl bonding to the less substituted terminus of the alkene. The adducts obtained from N-alkylformamidyls exist as mixtures of rotameric isomers whose configurations have been assigned. The reactivity of the formamidyl radical has been discussed in terms of its conformation and electronic state.

  DOI：

  10.1039/p19920000627
• 作为产物：
  描述：

  N-苄基甲酰胺 在 溴 、 碳酸氢钠 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 生成 甲酰胺,N-溴-N-(苯基甲基)-
  参考文献：
  名称：

  Photolytic and chromium(II)-promoted addition reactions of N-halogenoformamides with alkenes

  摘要：

  Formamidyl radicals (HCONR) do not intramolecularly abstract hydrogen or cyclise onto aromatic rings, but do add intermolecularly to alkenes. The photolytic addition of N-halogenoformamides to alkenes is inhibited by N-alkylation. However, N-alkyl-N-halogenoformamides add to alkenes in the presence of chromium(II) species. The addition of N-halogenoformamides to alkenes occurs regiospecifically with formamidyl bonding to the less substituted terminus of the alkene. The adducts obtained from N-alkylformamidyls exist as mixtures of rotameric isomers whose configurations have been assigned. The reactivity of the formamidyl radical has been discussed in terms of its conformation and electronic state.

  DOI：

  10.1039/p19920000627

文献信息

• Compounds and methods for treatment of thrombosis
  申请人：Abdel-Meguid S. Sherin

  公开号：US20050143317A1

  公开（公告）日：2005-06-30

  The present invention provides compounds that inhibit Factor XIa and methods of preventing or treating undesired thrombosis by administering a compound of the invention to a mammal. The invention also provides three-dimensional structures of Factor XIa and methods for designing or selecting additional Factor XIa inhibitors using these structures.

  本发明提供了能够抑制XIa因子的化合物，以及通过向哺乳动物投与本发明的化合物来预防或治疗不良血栓形成的方法。本发明还提供了XIa因子的三维结构以及利用这些结构设计或选择其他XIa因子抑制剂的方法。
• HETEROCYCLIC COMPOUNDS
  申请人：Ajinomoto Co., Inc.

  公开号：EP1396493A1

  公开（公告）日：2004-03-10

  A pharmaceutical composition containing a heterocyclic compound of the formula (I) wherein each symbol is as defined in the specification, an isomer thereof, a solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient has a superior TNF-α production suppressing action. Accordingly, it is useful for the prophylaxis or treatment of various diseases caused by abnormal production of TNF-α.

  一种含有式(I)杂环化合物的药物组合物 其中各符号如说明书中所定义）的杂环化合物、其异构体、其溶液或其药学上可接受的盐作为活性成分的药物组合物，具有优异的抑制 TNF-α 生成的作用。因此，它可用于预防或治疗由 TNF-α 的异常产生引起的各种疾病。
• Heterocyclic compounds
  申请人：——

  公开号：US20040147546A1

  公开（公告）日：2004-07-29

  A pharmaceutical composition containing a heterocyclic compound of the formula (I) 1 wherein each symbol is as defined in the specification, an isomer thereof, a solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient has a superior TNF-&agr; production suppressing action. Accordingly, it is useful for the prophylaxis or treatment of various diseases caused by abnormal production of TNF-&agr;.

  一种含有式 (I) 杂环化合物的药物组合物 1 其中各符号如说明书中所定义）的杂环化合物、其异构体、其溶液或其药学上可接受的盐作为活性成分的药物组合物，具有优异的 TNF-&agr; 生成抑制作用。因此，它可用于预防或治疗由 TNF-&agr; 异常产生引起的各种疾病。
• US7902179B2
  申请人：——

  公开号：US7902179B2

  公开（公告）日：2011-03-08